Skip Navigation

This under-the-radar stock can surge more than 60% on a possible treatment for immuno-inflammatory diseases, Goldman Sachs says

Published Thu, Dec 1 202210:02 AM ESTUpdated Thu, Dec 1 202211:44 AM EST

Sarah Min @_sarahmin

More In Analyst Calls

Forget Nvidia. Here are 5 undervalued tech stocks every investor should own, Goldman Sachs says

Forget Nvidia. Here are 5 undervalued tech stocks every investor should own, Goldman Sachs says

FanDuel parent Flutter joining the big leagues. Moving primary listing to U.S. from U.K. may spur investor interest

FanDuel parent Flutter joining the big leagues. Moving primary listing to U.S. from U.K. may spur investor interest

Barclays upgrades a little-known biotech stock that it says can more than double

Barclays upgrades a little-known biotech stock that it says can more than double